A drug galcanezumab, initially known as LY2951742, represents a significant step in migraine management. The chemical identity is that of a humanized monoclonal protein, specifically targeting the receptor. This https://opensocialfactory.com/story25893565/galcanezumab-a-deep-dive-into-ly2951742-and-its-chemical-identity